Evolution of the Average Target: XP Inc.

Evolution of the Target Price: XP Inc.

Changes in Analyst Recommendations: XP Inc.

dee27ed27cf480d04004d2510fd1a.HKyVHcmMOUNcIcqisenTRCEwOTsQ4uB5t__Mg6N3p6o.LePdbKv8YC8KEZPAxoeVImAIQ1AmoZkw8M2F1ZsA0dMp6qZFp9x-cmtJpQ~56a18dc14349f8f8ebed370ce1611fae
03/04 UBS Adjusts Price Target on XP to $28 From $25, Maintains Buy Rating MT
21/01 Jefferies Initiates XP at Buy With $22 Price Target MT
17/12 UBS Adjusts XP Price Target to $25 From $23, Maintains Buy Rating MT
17/10/25 UBS Adjusts Price Target on XP to $23 From $24, Maintains Buy Rating MT
24/06/25 XP Shares Drop After Downgrade From Itau BBA MT
23/06/25 Itau BBA Downgrades XP to Market Perform From Outperform, Adjusts Price Target to $21 From $20 MT
10/06/25 UBS Adjusts XP Price Target to $24 From $17, Maintains Buy Rating MT
04/06/25 Goldman Sachs Upgrades XP to Buy From Neutral, $23 Price Target MT
14/05/25 XP Shares Rise After Morgan Stanley Upgrades to Overweight From Equalweight MT
13/05/25 Morgan Stanley Upgrades XP to Overweight From Equalweight, Adjusts Price Target to $24 From $18 MT
08/04/25 UBS Adjusts Price Target on XP to $17 From $16, Keeps Buy Rating MT
18/03/25 Itau BBA Initiates XP at Outperform With $20 Price Target MT
25/01/25 XP Shares Rise After Upgrade From UBS MT
25/01/25 UBS Upgrades XP to Buy From Neutral, Cuts Price Target to $16 From $19 MT
11/12/24 BofA Securities Downgrades XP to Neutral From Buy, Price Target is $16 MT
26/11/24 UBS Cuts Price Target on XP to $19 From $21, Maintains Neutral Rating MT
11/07/24 UBS Downgrades XP to Neutral From Buy, Cuts Price Target to $21 From $30 MT
05/07/24 Bradesco BBI Downgrades XP to Neutral From Outperform, Cuts Price Target to $19 From $31 MT
06/06/24 Citigroup Adjusts Price Target on XP to $27 From $29, Maintains Buy Rating MT
01/05/24 XP Shares Decline After Goldman Sachs Downgrade MT
30/04/24 Goldman Sachs Downgrades XP to Neutral From Buy, Cuts Price Target to $23 From $30 MT
23/04/24 Morgan Stanley Downgrades XP to Equalweight From Overweight, Adjusts Price Target to $24 From $31 MT
23/03/24 Citigroup Adjusts Price Target on XP to $29 From $28, Maintains Buy Rating MT
12/12/23 UBS Adjusts XP Price Target to $30 From $31, Maintains Buy Rating MT
05/12/23 JPMorgan Upgrades XP to Overweight From Neutral, Raises Price Target to $30 From $27 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+41.15%
+29.22%
+2.84%
+54.9%
+39.3%
- - -3.38%
- - +39.85%
Average +29.13%
Weighted average by Cap. +28.09%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
85.58BRL
Average target price
121.98BRL
Spread / Average Target
+42.53%
High Price Target
135.64BRL
Spread / Highest target
+58.48%
Low Price Target
98.44BRL
Spread / Lowest Target
+15.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Jefferies & Co.
Itau BBA
Goldman Sachs
Morgan Stanley
BofA Securities
Citigroup
JPMorgan Chase
Credit Suisse
Bradesco
HSBC
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
85.58BRL
Average target price
121.98BRL
Spread / Average Target
+42.53%

Quarterly revenue - Rate of surprise